*Dear Editor,*

identifying risk factors for early progression toward severe disease and/or mortality is fundamental for the practical management of COVID-19 patients. Evidence shows that pro-inflammatory cytokines play a pivotal role in the pathophysiology of lung damage in patients affected by coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore we read with much interest the recent article published in Your Journal by Ye Q. et al. who describe the "cytokine storm" in COVID patients.[@bib0001] A lot of patients affected by COVID-19 develop a fulminant and damaging immune reaction sustained by cytokines leading to alveolar infiltration by macrophages and monocytes.[@bib0001] Interleukin-6 (IL-6) is one of the main mediators of inflammatory and immune response initiated by infection or injury and increased levels of IL-6 are found in more than one half of patients with COVID-19.[@bib0002] Levels of IL-6 seem to be associated with inflammatory response, respiratory failure, needing for mechanical ventilation and/or intubation and mortality in COVID-19 patients.[@bib0003] ^,^ [@bib0004] In a meta-analysis including nine studies (total 1426 patients) reporting on IL-6 and outcome in COVID-19, mean IL-6 levels were more than three times higher in patients with complicated COVID-19 compared with those with non complicated disease, and IL-6 levels were associated with mortality risk.[@bib0004] However, whether IL-6 could be a better prognosticator than clinical and laboratory variables remains unclear. Therefore, we tested the role of IL-6 as risk factor for negative outcome compared with other demographic and clinical variables or biomarkers collected at hospital admission. Age over 60 years, presence of at least one co-morbidity among arterial hypertension, diabetes, cardiovascular disease, asthma, chronic lung disease, chronic kidney disease, liver disease, HIV infections, and malignancy for at least 6 months, lymphocyte count under 1.0 × 10^9^/L, lactate dehydrogenase (LDH) over 500 U/L, CALL score \> 9 points (*C*=presence of co-morbidity, *A*=age over 60 years, *L*=lymphocyte count under 1.0 × 10^9^/L, *L*=LDH over 250 U/L or 500 U/L)[@bib0005], D-Dimer over 500 microg/L, and IL-6 over 25 pg/mL were the analyzed variables. Quantitative determination of IL-6 levels was performed by using an immunoenzymatic chemiluminescent assay (Access Immunoassay System, Beckman Coulter, USA, lowest limit of detection 0.5 pg/mL). After exclusion of patients requiring immediate intensive care unit (ICU) admission, we analyzed risk factors for the combined endpoint progression to severe COVID-19 syndrome and/or in-hospital mortality in an Italian COVID-19 population admitted to a non intensive ward from March 12 to April 20, 2020. Progression toward clinical worsening was defined as respiratory rate ≥ 30 breaths/min, resting SatO~2~ ≤ 93%, paO2/FiO2 ratio ≤ 300 or requiring of mechanical ventilation, such as in previous studies.[@bib0005] The study population consisted of 77 patients, 44 males (57.1%), with mean age 64 ± 17 years. Of them, 45 patients (58.4%) met criteria for the combined endpoint. Six patients (7.8%) died. CALL score \> 9 points (55.3% vs 26.6%, *p* = 0.0099) and IL-6 \> 25 pg/mL (65.9% vs 23.3%, *p* = 0.0004) were significantly more frequent in patients with the combined endpoint. At logistic regression analysis IL-6 over 25 pg/mL (OR 11.6, 95% CI 2.8--48,2) was found independent risk factor for the combined endpoint ([Table 1](#tbl0001){ref-type="table"} ). Mean levels of IL-6 in patients who met criteria for the combined endpoint were significantly higher compared with those of patients who did not (134.3 ± 19.5 vs 15.6 ± 14.8 pg/mL, *p* \< 0.001). The area under the receiver operating characteristic (ROC) curve (AUC) for IL-6 as predictor of the combined endpoint was 0.80 (95% CI 0.70--0.89) ([Fig. 1](#fig0001){ref-type="fig"} ). The AUC for IL-6 as predictor of in-hospital mortality was 0.90 (95% CI 0.81--0.95), while it was 0.75 (95% CI 0.64--0.84) for IL-6 as predictor of progression to severe COVID-19.Table 1Risk factors for the combined endpoint progression to severe COVID-19 and/or in-hospital mortality. Logistic regression analysis.Table 1VariableOdds ratio95% CIAge over 60 years1,48820,3663--6,0466CALL score \> 9 points4,55770,7383--28,1352Co-morbidity0,31500,0634--1,1561D-Dimer \> 500 microg/L0,98820,2638--3,7009IL-6 \> 25 pg/mL11,64602,8123--48,2277LDH \> 500 U/L0,50330,1061--2,3888Lymphocyte count\< 1.0 x 10^9^0,61450,1473--2,5638[^1]Fig. 1Receiver operating characteristic (ROC) curve showing the predictive power of IL-6 for predicting progression to severe COVID-19 and/or in-hospital mortality.Fig. 1

In conclusion, in our COVID-19 population, IL-6 levels at hospital admission seem to be a good prognosticator for the combined endpoint progression to severe disease and/or in-hospital mortality, and it seems to be the best prognosticator for negative outcome. Therefore, our study supports the hypothesis that targeting the cytokine storm induced by SARS-CoV-2 by using anti-IL-6 drugs could be a valid therapeutic option, together with supportive care strategies, for improving outcomes in COVID-19 patients.[@bib0006]

[^1]: CI: confidence interval; CALL score: *C*=presence of co-morbidity, *A*=age over 60 years, *L*=lymphocyte count under 1.0 x 10^9^/L, *L*=LDH over 250 U/L or 500 U/L; IL-6: Interleukin-6; LDH: lactate dehydrogenase.
